The histone demethylase JMJD1A, which controls gene expression by epigenetic regulation of H3K9 methylation marks, functions in diverse activities, including spermatogenesis, metabolism and stem cell self-renewal and differentiation. Here, we found that JMJD1A knockdown in prostate cancer cells antagonizes their proliferation and survival. Profiling array analyses revealed that JMJD1A-dependent genes function in cellular growth, proliferation and survival, and implicated that the c-Myc transcriptional network is deregulated following JMJD1A inhibition. Biochemical analyses confirmed that JMJD1A enhances c-Myc transcriptional activity by upregulating c-Myc expression levels. Mechanistically, JMJD1A activity promoted recruitment of androgen receptor (AR) to the c-Myc gene enhancer and induced H3K9 demethylation, increasing AR-dependent transcription of c-Myc mRNA. In parallel, we found that JMJD1A regulated c-Myc stability, likely by inhibiting HUWE1, an E3 ubiquitin ligase known to target degradation of several substrates including c-Myc. JMJD1A (wild type or mutant lacking histone demethylase activity) bound to HUWE1, attenuated HUWE1-dependent ubiquitination and subsequent degradation of c-Myc, increasing c-Myc protein levels. Furthermore, c-Myc knockdown in prostate cancer cells phenocopied effects of JMJD1A knockdown, and c-Myc re-expression in JMJD1A-knockdown cells partially rescued prostate cancer cell growth in vitro and in vivo. c-Myc protein levels were positively correlated with those of JMJD1A in a subset of human prostate cancer specimens. Collectively, our findings identify a critical role for JMJD1A in regulating proliferation and survival of prostate cancer cells by controlling c-Myc expression at transcriptional and post-translational levels.
INTRODUCTION
Histone methylation is an important epigenetic modification that determines whether a gene is transcriptionally active or inactive. Both histone methylation and demethylation are dynamically regulated by respective methyl transferases and demethylases. Methylation of histone 3 lysine-9 (H3K9) is a repressive histone mark associated with transcriptional inactivation. JMJD1A (also known as KDM3A or JHDM2A) is a histone demethylase that removes mono-and di-methyl groups from H3K9 (specifically, from H3K9me1 or H3K9me2), enabling transcriptional activation. [1] [2] [3] [4] Epigenetic regulation by JMJD1A reportedly functions in biological processes as diverse as spermatogenesis, metabolism, sex determination, stem cell self-renewal and differentiation. [3] [4] [5] [6] Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death in American men. 7 Studies show that androgen receptor (AR), a member of the nuclear receptor superfamily, plays a key role in prostate cancer initiation, progression and resistance to androgen-deprivation therapy. [8] [9] [10] Ligand-bound AR regulates gene expression by binding to androgen-responsive elements (AREs) of target genes and recruiting either co-activators or corepressors. Among the former, JMJD1A reportedly serves as an AR co-activator via H3K9 demethylation at promoters or enhancers of some AR target genes.
1 JMJD1A also functions in hypoxia-induced neuroendocrine differentiation of prostate cancer cells, 11 an aggressive phenotype associated with metastasis and resistance to therapy. 12 These findings suggest overall that JMJD1A may function in development and progression of prostate cancer. In addition, JMJD1A is shown to play a tumor-promoting role in several types of cancer cells such as colon carcinoma, 13 neuroblastoma, 14 hepatocellular carcinoma 15 and sarcoma. 16, 17 The proto-oncogene c-Myc is a master regulator for cell proliferation and transformation, and its activity underlies numerous cancers. 18 For example, overexpression of c-Myc can lead to the transformation of primary human prostate epithelial cells in vitro. 19 Prostate-specific overexpression of c-Myc alone promotes tumor development in mouse prostate, 20 and c-Myc cooperates with loss of the phosphatase PTEN (phosphatase and tensin homolog) to drive prostate cancer progression. [21] [22] [23] Overexpression of c-Myc is associated with prostate cancer recurrence and poor prognosis. 24, 25 c-Myc mRNA and proteins are reportedly upregulated in human prostate cancer tissues relative to normal prostate tissue. 26, 27 Potential mechanisms proposed to promote c-Myc upregulation include gene amplification, 28 regulation by the long-range enhancers 29 and transcriptional upregulation.
c-Myc is also subject to regulation by E3 ubiquitin ligases, including Fbxw7, Skp2, Pihr2 and HUWE1. HUWE1 (for HECT, UBA and WWE domain containing 1, also known as MULE) is a HECT family E3 ubiquitin ligase that regulates ubiquitinationdependent degradation of substrates including p53, 31 BRCA1, 32 Mcl-1, 33 TIAM1, 34 and Myc. 35, 36 A recent study reveals that HUWE1 functions as a tumor suppressor by promoting c-Myc degradation in a mouse model of RAS-driven skin carcinogenesis. 36 Here, we identify JMJD1A as essential for proliferation of prostate cancer cells, and show that c-Myc is a key downstream effector of JMJD1A in this process. We report that JMJD1A stabilizes c-Myc protein by inhibiting HUWE1 and also increases c-Myc transcription through AR-dependent transcriptional activation. Identifying these mechanisms highlights an undisclosed JMJD1A activity underlying prostate cancer tumorigenesis and suggests that JMJD1A could be targeted for prostate cancer therapies.
RESULTS

JMJD1A knockdown antagonizes tumorigenesis of prostate cancer cells
We previously reported that JMJD1A is upregulated in the Rv1 prostate cancer cells under hypoxia and contributes to the hypoxia-induced neuroendocrine differentiation. 11 To further investigate JMJD1A function in prostate cancer, we knocked down JMJD1A in the androgen-independent Rv1 cells via lentiviral transduction using two different JMJD1A short hairpin RNAs (shRNAs). Separately, both constructs reduced expression of JMJD1A mRNA ( Figure 1a ) and protein ( Figure 1b) . However, JMJD1A knockdown (KD) alone had no effect on hypoxia-induced expression of neuron-specific enolase, a neuroendocrine marker (Supplementary Figure S1A) . This result is consistent with our previous finding that simultaneous overexpression of three factors (Hes6, Sox9 and JMJD1A) was required for hypoxia-induced neuroendocrine differentiation, whereas overexpression of just one of those factors had no effect. 11 However, assessment of cell proliferation using an MTT assay showed that JMJD1A KD significantly inhibited Rv1 cell growth under both normoxia ( Figure 1c ) and hypoxia (Supplementary Figure S1B) . Specifically, in both normoxia and hypoxia, control Rv1 cells increased in number over 3 days, whereas the number of JMJD1A-KD cells remained unchanged (Figure 1c and Supplementary Figure S1B) , suggesting that JMJD1A functions in prostate cancer cell proliferation and/or survival. Given that JMJD1A functions similarly in Rv1 cell growth under both normoxia and hypoxia ( Figure 1c and Supplementary Figure S1B) , we focused our analysis here on conditions of normoxia only.
JMJD1A KD by either of two different shRNAs abolished Rv1 cell colony formation in a soft agar assay (Figure 1d ), a stringent indicator of anchorage-independent growth. Rv1 cells reportedly form spheres in three-dimensional (3D) Matrigel or in suspension, conditions that foster growth of cells that express stem cell markers and exhibit higher tumorigenic activity when injected into immuno-deficient mice. 37 Thus, we employed a sphere formation assay to assess potential cancer stem cell-like activity of Rv1 cells. JMJD1A KD abolished sphere formation by Rv1 cells in 3D Matrigel (Figures 1e and f ) or in suspension (data not shown), supporting the idea that JMJD1A is required for proliferation or survival of prostate cancer cells with stem cell-like properties.
To further test JMJD1A function in tumorigenesis, we employed an orthotopic prostate tumor model in which Rv1 cells are injected into the prostate of nude mice. In control mice, injection of Rv1 cells resulted in formation of large prostate tumors, whereas comparable injection of Rv1 cells transduced with either one of two different JMJD1A shRNAs indicated that JMJD1A KD abolished tumorigenesis, that is, no tumor formation by the JMJD1A-KD Rv1 cells (Figures 1g and h) Figure S1G) . Overall, these results show that JMJD1A KD abolishes long-term proliferation and survival of prostate cancer cells in vitro and in vivo.
JMJD1A promotes proliferation and survival of prostate cancer cells To determine whether JMJD1A regulates cell proliferation, we performed a bromodeoxyuridine (BrdU) incorporation assay using JMJD1A KD prostate cancer cells, including the androgen-sensitive Rv1 and LNCaP cells and the androgen-insensitive PC3 and DU145 cells. Equal numbers of control and JMJD1A-KD cells were treated with BrdU for 4 h, and the BrdU incorporation into the DNA was measured by the BrdU immunolabeling and chromogenic readout. JMJD1A KD reduced BrdU incorporation by ∼ 50% in all of the prostate cancer cell lines tested (Figure 1i ), indicating that JMJD1A is required for proliferation. To determine whether JMJD1A also regulates apoptosis, we stained prostate cancer cells with 4',6-diamidino-2-phenylindole to visualize the nuclear fragmentation, a marker of late apoptotic events. JMJD1A KD resulted in an ∼ 12-fold increase in the number of Rv1 cells exhibiting fragmented nuclei (Figure 1j and Supplementary Figure S1H ). In contrast, JMJD1A KD in LNCaP, PC3 or DU145 cells had no effect on nuclear fragmentation (Figure 1j ). Consistently, JMJD1A KD in Rv1 cells led to PARP (poly(ADP-ribose) polymerase) cleavage and activation of caspase-3 (markers of early apoptotic events) based on western blot analysis (Figure 1k ). JMJD1A KD in LNCaP, PC3 or DU145 cells ). (e and f) The effect of JMJD1A KD in Rv1 cells on sphere formation in Matrigel. Cells were grown for 10 days in Matrigel and the number of spheres per field was determined. JMJD1A KD abolished sphere formation (P o1 × 10 − 15 for pLKO.1 vs shJMJD1A-1 or shJMJD1A-2). (g and h) Effect of JMJD1A KD in Rv1 cells on prostate tumor formation in an orthotopic model. Rv1 cells (pLKO.1, shJMJD1A-1, or shJMJD1A-2) were injected into the dorsal prostates of nude mice. After 3 weeks, tumors were monitored and weighed (n = 5 for each group, P o1 × 10 − 4 for pLKO.1 vs shJMJD1A-1 or shJMJD1A-2). Images in (g) depict tumor formation in the mouse genitourinary tract. (i) Indicated prostate cancer lines transduced with either control pLKO.1 or shJMJD1A were incubated with 10 μM BrdU for 4 h and BrdU incorporation was then determined using a BrdU cell proliferation kit. The reading of absorbance at 490 nm is an indicator of BrdU levels in DNA. JMJD1A KD decreased BrdU incorporation (P o0.005 for Rv1, LNCaP or PC3, P o0.01 for DU145). (j) Prostate cancer cells transduced with either pLKO.1 or shJMJD1A were stained with 4',6-diamidino-2-phenylindole (DAPI), and the number of cells exhibiting fragmented nuclei was determined. JMJD1A KD induced nuclear fragmentation in Rv1 cells (P o1 × 10 − 14 ) but not in other prostate cancer cells (P40.1). (k) Various prostate cancer cell lines transduced with pLKO.1 control (#1) or shJMJD1A (#2) were analyzed by western blotting with indicated antibodies. had no effect on PARP cleavage or caspase-3 activation (Figure 1k) (Figure 1 ). Gene network analysis using IPA software was performed to identify possible enrichment of transcriptional networks among JMJD1A-dependent genes. Progesterone receptor (PR), AR, p53, c-Myc and activating protein 1 (AP-1) are the top five transcription factors predicted to be responsive to JMJD1A inhibition ( Figure 2b ). AR can serve as a positive control in this analysis because of the established role of JMJD1A as an AR co-activator. 1 The prediction of PR may be because of the alteration of AR target genes upon JMJD1A KD, as some of PR target genes defined by the IPA software are also the AR target genes, possibly because of the overlapping of binding motifs between AR and PR in the gene regulation. 39, 40 To confirm whether JMJD1A regulates the activity of transcription factors predicted by IPA analysis (Figure 2b ), we transfected Rv1 cells (either pLKO.1 control or shJMJD1A cells) with a luciferase reporter for AR, p53, c-Myc or AP-1. JMJD1A KD significantly inhibited the AR, c-Myc or AP-1 reporter but had no effect on p53 reporter activity (Figure 2c ). These results suggest that JMJD1A can regulate multiple transcription factors. Because of the key role of c-Myc in prostate cancer, we determined to focus on role of c-Myc in JMJD1A-dependent proliferation of prostate cancer cells.
To promote cell proliferation and survival, c-Myc reportedly represses transcription of several cyclin-dependent kinase (CDK) inhibitors and GADD45 in a cell-type and context-dependent manner.
36,41-43 Thus, we employed real-time quantitative reverse transcription-PCR to examine transcript levels of CDKN1A (p21), CDKN1B (p27), CDKN1C (p57), CDKN2B (p15), CDKN2C (p18), GADD45A and GADD45B. Among these genes, only CDKN1A (p21) and CDKN2B (p15) were consistently upregulated in either JMJD1A-KD or c-Myc-KD cells (Figures 2d and e, data not shown). JMJD1A KD also activated the CDKN1A (p21) promoter, as reflected by increased activity of a p21 promoter-driven luciferase reporter relative to controls ( Figure 2f ). To determine whether JMJD1A regulates c-Myc binding to CDKN1A (p21) and CDKN2B (p15) promoters, we performed chromatin immunoprecipitation using control (pLKO.1) or JMJD1A-KD Rv1 cells and found that JMJD1A KD decreased binding of c-Myc to both promoters (CDKN1A, Figure 2g ; CDKN2B, Figure 2h ).
Taken together, the above results suggest that JMJD1A promotes c-Myc transcriptional activities. Figure S2B) . c-Myc KD in Rv1 cells resulted in an ∼ eightfold increase in nuclear fragmentation (Supplementary Figure S2C) , whereas c-Myc KD in other prostate cancer cell lines (LNCaP, PC3 or DU145) had no effect (Supplementary Figure S2C) . The prostate cancer cells (Rv1, LNCaP, PC3 or DU145) with c-Myc KD also showed significantly inhibited colony formation (Supplementary Figure S2D) . Overall, c-Myc KD phenotypes resembled those of JMJD1A KD in prostate cancer cells (Rv1, LNCaP, PC3 and DU145), suggesting that c-Myc may be a downstream effector of JMJD1A.
JMJD1A promotes AR-dependent c-Myc expression Our profiling array data showed a twofold decrease in c-Myc mRNA levels following JMJD1A KD in Rv1 cells (Supplementary Table S1 Figure S3A ), but had no effect on the expression of JMJD1A (Supplementary Figure S3B) . To determine whether that effect was AR dependent, we knocked down JMJD1A in Rv1 or LNCaP cells stably expressing AR shRNA. Although JMJD1A KD reduced c-Myc mRNA in control cells that express normal levels of AR, it failed to do so in AR-KD cells: thus the effect of JMJD1A and AR double KD was similar to the effect of AR KD alone (Figure 3d ). These results suggest that JMJD1A regulation of c-Myc mRNA is AR dependent.
JMJD1A promotes recruitment of AR to the c-Myc gene enhancer independent of androgen We next asked how JMJD1A increases AR-dependent c-Myc transcription. Because JMJD1A is a co-activator of AR, 1 and the c-Myc gene enhancer contains an ARE, 44 we performed a chromatin immunoprecipitation assay using a JMJD1A antibody to determine whether JMJD1A associates with the ARE on the c-Myc enhancer. We observed association of JMJD1A with the c-Myc enhancer ARE and confirmed specificity of that interaction by JMJD1A KD that reduced JMJD1A binding to the enhancer (Figure 3e ). We observed similar results when we assessed JMJD1A binding to the prostate-specific antigen (PSA) enhancer that served as a positive control (Supplementary Figure S3C Figure S3D) . The latter result is consistent with the previous report that JMJD1A does not alter binding of AR to the PSA enhancer.
1 Consistent with the role of JMJD1A as a H3K9me2 demethylase, knockdown of either JMJD1A or AR increased levels of the H3K9me2 mark at the c-Myc (Figure 3g ) or PSA (Supplementary Figure S3E) enhancers. These results suggest that JMJD1A increases c-Myc transcription both by promoting AR recruitment and demethylating the c-Myc enhancer.
To determine whether JMJD1A-dependent transcription of c-Myc requires the AR ligand, we maintained the prostate cancer cells (pLKO.1 or shJMJD1A) in the media supplemented with charcoal-stripped fetal bovine serum that contains extremely low levels of androgen for 2 days, followed by treatment of cells with or without synthetic androgen R1881 for 1 day. Although R1881 induced the PSA transcript slightly in Rv1 cells (Figure 3h ) and strongly in LNCaP cells (Figure 3i) , it failed to induce the c-Myc transcript in either Rv1 (Figure 3h ) or LNCaP cells (Figure 3i) , and knockdown of JMJD1A reduced the c-Myc transcript similarly with or without R1881 (Figures 3h and i) . These results suggest that AR ligand is not required for JMJD1A-dependent transcription of c-Myc. To further confirm this conclusion, we performed chromatin immunoprecipitation assay using AR antibody on LNCaP cells (pLKO.1 or shJMJD1A). Even in the absence of R1881, we observed the binding of AR to the c-Myc gene enhancer in the LNCaP control cells (pLKO.1), and such binding was not affected by the treatment of R1881 (Figure 3j ). Knockdown of JMJD1A equally reduced the binding between AR and c-Myc enhancer in the presence or absence of R1881 (Figure 3j ). In contrast, little AR was associated with PSA enhancer in the absence of R1881, and the binding of AR to PSA enhancer was highly enhanced by R1881 (Figure 3j) . These results reveal a constitutive association between AR and c-Myc enhancer and the requirement of JMJD1A for such association in the presence or absence of androgen. Our result is consistent with the previous report showing that AR upregulates the expression of c-Myc in a ligand-independent manner. 44 To determine whether histone demethylase activity is required for c-Myc expression, we knocked down endogenous JMJD1A in Rv1 cells and re-expressed JMJD1A constructs encoding either the wild-type protein or a catalytic site mutant that has no demethylase activity. 1 Both constructs harbored mutations in the JMJD1A shRNA targeting site that made them resistant to gene silencing and enabled us to knock down endogenous JMJD1A and simultaneously re-express wild-type or mutant constructs. In JMJD1A-KD Rv1 cells, c-Myc mRNA and protein levels were fully rescued by wild-type JMJD1A (Figures 3k and l) . In contrast, catalytically inactive JMJD1A did not rescue c-Myc mRNA expression following JMJD1A KD (Figure 3k ) but partially rescued c-Myc protein expression, suggesting that JMJD1A histone demethylase activity is required for c-Myc transcription. Interestingly, partial rescue of c-Myc protein by catalytically inactive JMJD1A suggests transcription-independent regulation of c-Myc expression in prostate cancer cells. To do so, we first confirmed interaction between ectopically expressed JMJD1A and HUWE1 by co-immunoprecipitation in 293T cells (Supplementary Figures S4A and B) . We also confirmed interaction between endogenous JMJD1A and HUWE1 by coimmunoprecipitation in Rv1 cells (Figure 4a ). To test whether JMJD1A/HUWE1 interaction had any effect on HUWE1-dependent c-Myc degradation, we co-expressed HUWE1 and c-Myc with JMJD1A in 293T cells. Western blot analysis showed that HUWE1 overexpression reduced c-Myc levels, an effect abolished by coexpression of JMJD1A (Figure 4b and Supplementary Figure S4C) . Of note, overexpression of the catalytically inactive form of JMJD1A also blocked HUWE1-induced c-Myc degradation (Figure 4b ), indicating that JMJD1A histone demethylase activity is not required for this activity. To determine whether JMJD1A affects the HUWE1-induced degradation of c-Myc in prostate cancer cells, we overexpressed HUWE1 in PC3 cells with or without JMJD1A coexpression. Western blot analysis showed that HUWE1 overexpression reduced the endogenous c-Myc level, whereas such an effect was attenuated upon JMJD1A coexpression (Supplementary Figure S4D) .
JMJD1A increases c-
JMJD1A overexpression did not alter HUWE1-induced degradation of p53 (Figure 4c) , a different HUWE1 substrate, 31 and JMJD1A KD in prostate cancer cells had no effect on p53 protein levels (Figure 1k ), suggesting that JMJD1A inhibits HUWE1-mediated degradation of specific substrates, such as c-Myc.
JMJD1A overexpression had no effect on HUWE1 levels (Figures 4b and c and Supplementary Figure S4C) , suggesting that JMJD1A does not affect HUWE1 expression. HUWE1 overexpression also did not decrease JMJD1A levels (Figure 4c and Supplementary Figure S4C) , suggesting that JMJD1A does not undergo HUWE1-dependent degradation. Instead, JMJD1A levels increased upon HUWE1 overexpression (Figure 4c and Supplementary Figure S4C and S4D) , possibly because JMJD1A/HUWE1 interaction stabilizes JMJD1A, an issue we will address in a separate study.
To determine how JMJD1A inhibits c-Myc degradation promoted by HUWE1, we mapped interaction domains among the three proteins. To assess JMJD1A/HUWE1 interaction, we coexpressed full-length HUWE1 with the N-or C-terminal fragments of JMJD1A in 293T cells. Coimmunoprecipitation and western blot analysis revealed that the JMJD1A N-terminal half interacted with HUWE1 (Supplementary Figure S4E) . HUWE1 consists of an N-terminal ARLD domain, followed by UBA, WWE, BH3 and acidic regions, plus a C-terminal HECT domain (Figure 4d ). To determine which domain(s) interacts with JMJD1A, we engineered HUWE1 truncation mutants (Figure 4d ), each containing a single domain, and coexpressed them with full-length JMJD1A in 293T cells. Coimmunoprecipitation and western blot analyses indicated that HUWE1 fragments containing either the acidic region (F5) or HECT domain (F7) interacted with JMJD1A (Figure 4e) . When we asked which HUWE1 domain(s) was required for c-Myc interaction, we found that HUWE1 fragments containing the acidic region (F5) or the WWE domain (F3) interacted with c-Myc (Figure 4f (Figure 4j ), likely because HUWE1 knockdown has little or no effect on JMJD1A regulation of c-Myc transcription. These results further support the idea that JMJD1A regulates c-Myc at both post-translational and transcriptional levels.
c-Myc is a downstream effector of JMJD1A in prostate cancer cell tumorigenesis IPA analysis suggested that JMJD1A regulates multiple transcriptional networks in addition to c-Myc (Figure 2b) . To assess the effect of c-Myc on JMJD1A-dependent tumorigenesis, we reexpressed c-Myc in JMJD1A-KD Rv1 cells using a lentiviral vector encoding c-Myc. We have optimized the lentiviral transduction condition to restore c-Myc expression in JMJD1A-KD cells to the endogenous level as seen in the pLKO.1 control cells (Figure 5a and Supplementary Figure S5) . This approach will allow us to evaluate the specific effect of c-Myc downstream of JMJD1A. c-Myc re-expression partially rescued colony formation in soft agar by JMJD1A-KD Rv1 cells (Figure 5b) . Similarly, c-Myc re-expression in JMJD1A-KD PC3 or LNCaP cells partially rescued anchorageindependent growth of these cells in soft agar (Figure 5c and Supplementary Figure S5) , as well as sphere formation by JMJD1A-KD Rv1 cells in 3D Matrigel (Figure 5d ). The latter finding is consistent with the report that c-Myc is important to the maintenance of prostate cancer stem-like cells. 37 We next addressed the role of c-Myc downstream of JMJD1A in vivo using an orthotopic prostate tumor model in which Rv1 cells expressing luciferase are injected into the dorsal prostate of nude mice and tumor formation is monitored using an in vivo imaging system. In contrast to control cells, which formed large prostate tumors, we detected no tumor formation in mice injected with the JMJD1A-KD Rv1 cells (Figures 5e and f) . c-Myc reexpression in injected JMJD1A-KD Rv1 cells partially rescued tumor formation, although tumor size was only 30% of that of control cell-derived tumors (Figures 5e and f) . These results support a role for c-Myc in JMJD1A-dependent tumorigenesis of prostate cancer cells and suggest potential involvement of other JMJD1A effector(s) in tumorigenesis.
High c-Myc levels correlate with JMJD1A overexpression in a subset of human prostate specimens To confirm the relevance of our findings to human prostate cancer, we evaluated expression of JMJD1A and c-Myc in a human prostate cancer tissue microarray containing representative samples of Gleason stage 3-4 tumors (Figures 6a and b) . JMJD1A and c-Myc expression was primarily nuclear, but weak cytoplasmic staining of both proteins was also seen in some samples (Figure 6a ). Based on respective staining intensity, we defined c-Myc samples as either c-Myc low or high. JMJD1A staining was likewise defined as either JMJD1A low or high. Analysis to evaluate JMJD1A or c-Myc staining levels (Figure 6b) showed that although low c-Myc staining was not correlated with low JMJD1A staining, c-Myc-high staining was positively correlated with JMJD1A-high samples (Po 0.05, Fisher's exact test), suggesting a potential association of these factors in human prostate tumors. JMJD1A reportedly regulates gene expression through H3K9 demethylation. 1, 4, 13, 45 Consistent with its established role as an AR co-activator, we found that JMJD1A can recruit AR to the c-Myc enhancer and demethylate H3K9me2 at that locus. We also found that androgen is not required for the JMJD1A-dependent binding of AR to c-Myc enhancer. The latter finding is consistent with the report that AR upregulates c-Myc mRNA independent of its ligand in prostate cancer cells, and AR/c-Myc mRNAs are strongly correlated in the tissues of castration-resistant prostate cancer. 44 Furthermore, our rescue experiment using the catalytically inactive form of JMJD1A demonstrates that its histone demethylase activity is required for c-Myc transcription. In addition to this function, we identify a new, histone demethylase-independent role for JMJD1A in regulating c-Myc protein: JMJD1A binds to the ubiquitin ligase HUWE1 and inhibits its interaction with c-Myc, thereby increasing c-Myc protein levels by attenuating its ubiquitination and subsequent degradation. Therefore, our study Similar to other E3 ubiquitin ligases, HUWE1 likely destabilizes several substrates. [31] [32] [33] [34] 36 We report that JMJD1A interacts with HUWE1 fragments containing the HECT domain or the acidic region, and that it inhibits degradation of oncogenic c-Myc but not the tumor suppressor p53, both known HUWE1 substrates. Thus, JMJD1A provides a layer of regulation for selective degradation of HUWE1 substrates such as c-Myc. These findings support a tumor suppressor function for HUWE1 in prostate cancer cells based on its degradation of c-Myc, a concept recently advanced in a skin cancer model using the HUWE1 knockout mice. 36 c-Myc mRNA and proteins are upregulated in prostate cancer, 26, 27 and c-Myc overexpression drives prostate cancer progression. [21] [22] [23] Nonetheless, the mechanisms leading to c-Myc overexpression remain unclear. 27 Here, we find that JMJD1A can increase c-Myc expression in prostate cancer cell lines. More importantly, we observe that high levels of c-Myc are correlated with high JMJD1A levels in a prostate cancer tissue microarray, suggesting that JMJD1A contributes to c-Myc overexpression in a subset of human prostate cancers. Although several E3 ubiquitin ligases reportedly promote c-Myc degradation, it is not known whether any ubiquitin ligase regulates c-Myc expression in prostate cancer. Regulation of c-Myc protein by the JMJD1A/ HUWE1 axis is evidence that the ubiquitin-proteasome system likely contributes to c-Myc overexpression observed in human prostate cancer. Growth of prostate cancer cells upon JMJD1A KD was partially rescued by c-Myc re-expression. However, that effect was moderate, particularly in the orthotopic tumor model. These observations suggest that in addition to regulation of c-Myc expression, there might be additional layers of modulation of were injected into mouse prostate (n = 5 for each group). After 3 weeks, mice were injected with luciferin (i.p.), and tumor formation was monitored using in vivo bioluminescence imaging. (f) Tumor weights of mice described in (e) were determined. c-Myc function by JMJD1A. Alternatively, these observations suggest that JMJD1A may also regulate other downstream effectors in prostate cancer cells. IPA analysis of profiling array data and luciferase reporter assay implicate that JMJD1A KD may alter the activity of transcription factor AP-1 that has been implicated in prostate cancer development and progression. 46, 47 Future studies are needed to determine whether JMJD1A regulates the transcriptional activity of c-Myc and AP-1 as co-activators, and whether other transcription factors function in JMJD1A-dependent proliferation or survival of prostate cancer cells.
DISCUSSION
JMJD1A KD in prostate cancer cells blocked cell proliferation over days, and abolished colony formation by these cells in soft agar, supporting a function for JMJD1A in long-term cell proliferation and survival. Importantly, JMJD1A-KD Rv1 cells could not form spheres in 3D Matrigel or in suspension, methods commonly used to assess cancer stem cell activity. 37, 48, 49 Such spheres formed by Rv1 cells are known to enrich in highly tumorigenic cancer stem cell populations. 37 These results strongly suggest that JMJD1A is required for both bulk tumor and cancer stem-like cell populations in prostate cancer. Notably, Jmjd1a knockout mice are viable and show variable phenotypes including spermiogenic defects, 5 obesity 4 and male-to-female sex reversal. 3 Given these relatively mild phenotypes and the strong inhibitory effect of JMJD1A KD on prostate cancer cell growth, JMJD1A could serve as a therapeutic target for aggressive prostate cancers. Inhibitors targeting Jmj demethylase activity have been developed, but specific JMJD1A inhibitors are not yet available. Our results demonstrating catalysisdependent and -independent JMJD1A regulation of c-Myc expression suggest that JMJD1A motifs governing both catalytic activity and protein-protein interactions could be targeted in development of JMJD1A inhibitors. 
MATERIALS AND METHODS
Antibodies and reagents
Cell lines
LNCaP, PC3 and DU145 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Rv1 cells were kindly provided by Dr James Jacobberger (Cleveland, OH, USA). These cells are maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and antibiotics, and regularly tested to ensure that they are mycoplasma free.
Animal studies
Athymic nude mice were purchased from the Jackson Laboratory (Sacramento, CA, USA) and housed in the animal facility at SanfordBurnham Medical Research Institute (La Jolla, CA, USA) or the University of Maryland School of Medicine (Baltimore, MD, USA). All experiments were approved by the institutional animal care and use committee (no. 10-093, no. 0613011) and conducted following the animal policy of both Institutes in accordance with the National Institutes of Health guidelines.
Prostate tumor samples
A total of 38 prostate cancer specimens with a Gleason score 3-4 were obtained from the Vancouver Prostate Tissue Bank at the University of British Columbia (Clinical Research Ethics Board number: H09-01628). All specimens were from radical prostatectomy. Hematoxylin and eosin slides were reviewed and desired areas were marked. The tissue microarray was manually constructed (Beecher Instruments, Silver Spring, MD, USA) by punching duplicate cores of 1 mm from each sample.
Statistical analysis
The in vitro experiments were repeated at least three times. Data are presented as the mean ± s.d. Student's t-test (two tailed) was used to compare the difference between two groups of data sets with similar variance. Fisher's exact test was used to assess the relationship between immunohistochemistry staining. Po 0.05 was considered statistically significant. Support by NCI Grant CA154888 (to JQ) and a Merit Review Award Department of Veterans Affairs (to AH) is gratefully acknowledged.
